IRIS
SICURANZA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.459
NA - Nord America 2.100
AS - Asia 358
AF - Africa 19
OC - Oceania 7
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 4.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.087
GB - Regno Unito 670
IE - Irlanda 522
IT - Italia 439
RU - Federazione Russa 233
SE - Svezia 200
CN - Cina 163
FR - Francia 105
SG - Singapore 92
UA - Ucraina 91
DE - Germania 79
FI - Finlandia 62
VN - Vietnam 31
TR - Turchia 16
IN - India 14
EG - Egitto 12
IR - Iran 12
CZ - Repubblica Ceca 11
BE - Belgio 10
CA - Canada 10
NL - Olanda 9
JP - Giappone 8
AU - Australia 6
CI - Costa d'Avorio 5
HK - Hong Kong 5
PT - Portogallo 4
AT - Austria 3
MY - Malesia 3
PL - Polonia 3
BO - Bolivia 2
CH - Svizzera 2
DZ - Algeria 2
EE - Estonia 2
ES - Italia 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
ID - Indonesia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LT - Lituania 2
MX - Messico 2
PK - Pakistan 2
SA - Arabia Saudita 2
A1 - Anonimo 1
AR - Argentina 1
AZ - Azerbaigian 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.951
Salva come PNG Salva come JPEG
Città #
Southend 624
Dublin 518
Fairfield 368
Ashburn 210
Chandler 185
Woodbridge 158
Siena 143
Wilmington 125
Seattle 122
Cambridge 107
Ann Arbor 96
Houston 94
Singapore 76
Jacksonville 72
Princeton 63
New York 47
Helsinki 46
Beijing 43
Florence 38
Dong Ket 31
Nanjing 29
Dearborn 22
Shanghai 21
Moscow 18
San Mateo 17
London 15
Rome 15
Izmir 14
Milan 14
San Diego 14
Washington 14
Boardman 12
Brno 10
Brussels 10
Munich 10
Turin 10
Fremont 7
Los Angeles 7
Nanchang 7
Shenyang 7
Cairo 6
Jinan 6
Kunming 6
Abidjan 5
Düsseldorf 5
Frankfurt am Main 5
Hebei 5
Hefei 5
Hong Kong 5
Lappeenranta 5
Redwood City 5
Taizhou 5
Toronto 5
Zanjan 5
Dallas 4
Fano 4
Hangzhou 4
Sacramento 4
San Francisco 4
Tianjin 4
Tokyo 4
Vienna 4
Amsterdam 3
Bologna 3
Buscate 3
Chicago 3
Como 3
Council Bluffs 3
Detroit 3
Guangzhou 3
Gussago 3
Leawood 3
Lisbon 3
Montecatini Terme 3
Mumbai 3
New Bedfont 3
Ningbo 3
Palermo 3
Prescot 3
Salerno 3
Trieste 3
Abbadia San Salvatore 2
Alexandria 2
Almaty 2
Andover 2
Arezzo 2
Athens 2
Bangalore 2
Bethesda 2
Bishkek 2
Bitetto 2
Blida 2
Boston 2
Campi Bisenzio 2
Castiglion Fiorentino 2
Chennai 2
Chiampo 2
Chiswick 2
Columbus 2
Dammam 2
Totale 3.639
Salva come PNG Salva come JPEG
Nome #
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 216
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 204
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 198
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 197
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 197
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 172
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 172
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 167
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 165
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 165
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 161
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 155
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 149
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 144
Peptide vaccines for hematological malignancies: a missed promise? 140
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 133
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 117
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 116
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 116
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 109
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 108
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 106
Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma 102
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 97
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) 88
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 84
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia 81
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 79
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 79
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 78
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden 74
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 71
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 62
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 61
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 59
The role of tumor-associated macrophages in hematologic malignancies 56
CD26/DPP-4 in Chronic Myeloid Leukemia 55
DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response/MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study 53
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 52
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 51
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 45
Drug resistance and minimal residual disease in multiple myeloma 43
Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow 39
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 37
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 35
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 33
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 33
Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation 32
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 31
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis 30
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy 27
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 23
Totale 5.097
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.217
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.217
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020569 0 0 0 0 55 98 68 126 79 77 30 36
2020/2021771 31 51 25 78 68 59 80 89 66 89 52 83
2021/2022609 42 71 33 55 39 18 26 18 42 41 108 116
2022/2023834 42 94 106 82 60 130 30 86 76 11 94 23
2023/20241.026 31 32 95 62 53 246 330 23 12 41 23 78
2024/2025449 35 61 215 99 39 0 0 0 0 0 0 0
Totale 5.097